Core Insights - The company aims to become a leader in the nutrition and health sector with a strategic roadmap for 2026-2028, focusing on global expansion and innovation [1][3] - The company plans to enhance its core capabilities through product innovation and operational efficiency, while also adapting to new consumer demands [1][2] Strategic Goals - The core objective is to transition from being the top player in China to a global leader, with a focus on differentiated growth strategies across regions [1] - The China region will drive revenue and profit growth through high-growth channels such as MCN, private domain, cross-border e-commerce, and new retail supermarkets [1] - The Americas will focus on establishing challenger brands and strengthening local capabilities, while Europe will expand production capacity and optimize customer structure to improve gross margins [1] - The Asia-Pacific region will leverage the Thailand factory as a model to penetrate the Australian and Southeast Asian markets [1] Core Competencies - The company is enhancing its product quality and speed by establishing an anti-aging research institute and focusing on innovative raw materials and processes [1] - It aims to reduce costs and improve efficiency through scale effects and refined operations, while also deepening differentiated services to create premium value for customers [1] - The company is building flexible production capacity and an agile delivery system to quickly respond to market demands [1][2] Digitalization and New Business Opportunities - Digitalization initiatives, including "dark factories," AI formulation engines, and CRM systems, are being implemented to enhance overall process efficiency [2] - New business ventures are focusing on AI-driven precise nutrition and pet services, with a gradual exploration of the TOC model for long-term growth [2] Global Expansion and Capital Empowerment - The company has established seven production bases and five R&D centers, covering over 50 countries, indicating a robust global presence [2] - Plans for an H-share listing are underway, which would address long-term funding needs and support the effective implementation of international strategies [2] Business Divestiture - The company plans to divest its BF personal care business, which has been underperforming and lacks synergy with its core nutrition health business, to improve overall financial performance [2][3] Financial Projections - Revenue projections for 2025-2027 are estimated at 4.45 billion, 4.94 billion, and 5.57 billion yuan, reflecting year-on-year growth of 6%, 11%, and 13% respectively [3] - Expected net profits for the same period are projected at 260 million, 390 million, and 500 million yuan, with year-on-year changes of -21%, 51%, and 29% respectively [3] - The company is assigned a PE ratio of 30, 20, and 15X for the years 2025, 2026, and 2027, respectively, with a "recommended" rating [3]

Group 1: Stock Trading and Corporate Actions - Jia Mei Packaging's stock will resume trading on January 12, 2026, after a price increase of 230.48% from December 17, 2025, to January 6, 2026, which led to a temporary suspension for investigation [1] - Yanjiang Co. continues to suspend its stock trading due to uncertainties related to a potential major asset restructuring, with a trading plan expected to be disclosed by January 19, 2026 [1] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [4] - Xianle Health plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [4] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [4] Group 2: Mergers and Acquisitions - Defu Technology has terminated its acquisition of 100% of Luxembourg Copper Foil due to additional restrictions imposed by the Luxembourg Ministry of Economy [2] - Defu Technology intends to acquire at least 51% of Huiru Technology through cash purchase and capital increase, with Huiru becoming a subsidiary post-transaction [3] Group 3: Financial Performance and Forecasts - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, with automotive parts business growth offset by challenges in the home appliance sector [7] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [8] - Qu Mei Home expects negative profit figures for 2025, with a reported loss of approximately 66.93 million yuan for the first nine months of 2025 [9] - Jinzhongzi Liquor forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [10] - Sichuang Electronics predicts a net loss of 265 million to 340 million yuan for 2025, attributed to competitive pressures and delayed customer orders [11] - Wansheng Co. anticipates a net loss for 2025 [12] - Weiyuan Co. expects a net loss for 2025 [13] - Kosen Technology forecasts a net loss for 2025 due to market demand fluctuations and strategic adjustments [13] - Zhongheng Group predicts a net loss for 2025 [13] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, a year-on-year increase of 9.41% [13] Group 4: Shareholder Actions - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades between February 4 and April 30, 2026 [14] - Meidike's shareholder intends to reduce holdings by up to 1% through centralized bidding [14]

（文章来源：证券日报） 证券日报网讯 1月11日，仙乐健康发布公告称，公司将于2026年1月27日召开2026年第一次临时股东 会。 ...

（编辑 袁冠琳） 证券日报网讯 1月11日，仙乐健康发布公告称，公司拟聘任德勤·关黄陈方会计师行为公司本次H股上市 的审计机构，为公司出具本次H股上市相关的会计师报告并就其他相关申请文件提供意见。公司拟在本 次H股上市后聘任德勤·关黄陈方会计师行为公司本次H股发行并上市后首个会计年度的境外审计机构。 ...

Investment Rating - The investment rating for the company is "Accumulate" [5] Core Insights - The company has signed a non-binding letter of intent for the acquisition of 100% equity in Best Formulations PC LLC (BFPC), which is expected to optimize its U.S. business structure and enhance overall profitability [1] - The company plans to issue H shares and list on the Hong Kong Stock Exchange, aiming to leverage international capital markets to accelerate its global expansion and diversify its capital operations [2] - The introduction of AI nutritionists and the JsRight precision nutrition brand is a strategic move to tap into the growing demand for personalized nutrition, aligning with consumer trends towards evidence-based health solutions [2] Financial Performance Summary - Revenue projections for 2025-2027 are estimated at 4.557 billion, 5.021 billion, and 5.539 billion CNY respectively, with growth rates of 8.2%, 10.2%, and 10.3% [4] - The net profit attributable to the parent company for the same period is forecasted to be 3.07 billion, 4.07 billion, and 5.00 billion CNY, reflecting a year-on-year change of -5.5%, +32.5%, and +22.8% [3][4] - The current price-to-earnings (P/E) ratios are projected to be 25, 19, and 15 times for the years 2025, 2026, and 2027 respectively [3][4] Revenue Breakdown - For the first half of 2025, the company's revenue from different regions is as follows: Mainland China 8.2 million, Americas 7.6 million, Europe 3.6 million, and other regions 1.0 million, accounting for 40.1%, 37.2%, 17.6%, and 5.1% of total revenue respectively [2]

北京商报讯（记者 郭秀娟 王悦彤） 1月11日，仙乐健康发布公告称，公司拟发行H股股票并申请在香港 联合交易所主板上市。此举旨在深化公司全球化战略布局，利用国际资本市场优势，提升资本实力和综 合竞争力，加快海外业务发展，完善境内外双循环格局。 ...

Group 1 - Jia Mei Packaging's stock will resume trading on January 12, 2026, after completing a review due to a 230.48% price increase from December 17, 2025, to January 6, 2026 [1] - Yan Jiang Co. continues to suspend trading as it plans to acquire assets, with a disclosure expected by January 19, 2026 [2] - Defu Technology terminated its acquisition of 100% of Luxembourg Copper Foil due to restrictions from the Luxembourg Ministry of Economy, with a refund of €17.4047 million expected [3] Group 2 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash and capital increase, with Huiru focusing on high-performance electrolytic copper foil [4] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [5] - Xianle Health intends to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [6] Group 3 - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital, with a potential cancellation of unsold shares [7] - Fangsheng Pharmaceutical's production facility failed a GMP compliance check, but it will not significantly impact operations [8][9] - East China Pharmaceutical's subsidiary's product has been included in the list of breakthrough therapeutic varieties for severe hypertriglyceridemia [10] Group 4 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, primarily due to competitive pressures and foreign exchange losses [12] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [13] - Qu Mei Home expects a net loss for 2025, with significant negative figures reported for the first nine months [14] Group 5 - Jinzongzi Wine forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [15] - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for 2025, attributed to market competition and delayed orders [16] - Wansheng Co. anticipates a net loss for 2025 [17] - Weiyuan Co. also expects a net loss for 2025 [19] - Kosen Technology predicts a net loss for 2025 due to low capacity utilization and strategic adjustments [20] - Zhongheng Group expects a net loss for 2025 [21] Group 6 - Xiantan Co. reported a 9.41% year-on-year increase in chicken product sales revenue to 530 million yuan in December 2025 [22] Group 7 - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades [24] - Meidike shareholders plan to reduce their holdings by up to 1% through market transactions [25]

每经AI快讯，仙乐健康1月11日晚间发布公告称，公司第四届第十七次董事会会议于2026年1月8日在上 海市长宁来福士33楼公司会议室以现场会议与通讯表决相结合的方式召开。会议审议了《关于确定董事 会授权人士的议案》等文件。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——美国强掳马杜罗，觊觎格陵兰，为美元霸权"续命"！全球20%石油结算已弃 用美元，38万亿美债压顶，"石油-美债"体系遭重创 （记者 王晓波） ...

仙乐健康科技股份有限公司 董事会战略委员会工作细则 仙乐健康科技股份有限公司 董事会战略委员会工作细则 （草案） 第八条 经董事长提议并经董事会讨论通过，可对委员会委员在任期内进行 调 整。 （H 股发行上市后适用） 第一章 总 则 第一条 为适应仙乐健康科技股份有限公司（以下简称"公司"）战略发展 需要，增强公司核心竞争力，提高重大投资决策的效益和决策的质量，完善公司 治理结构，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《香港联合 交易所有限公司证券上市规则》等法律法规和《仙乐健康科技股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，公司设立董事会战略委员会，并制定 本工作细则。 第二条 战略委员会是董事会设立的专门工作机构，主要负责对公司长期发 展战略和重大投资决策进行研究并提出建议。 第二章 战略委员会的产生与组成 第三条 战略委员会成员由至少三名董事组成，董事长为委员之一。 第四条 除董事长外的其他战略委员会委员由董事长、二分之一以上的独立 非执行董事或者三分之一以上的全体董事提名，并由董事会选举产生。 第五条 战略委员会设召集人一名，负责主持战略委员会工作，由董事长担 任。 ...

仙乐健康科技股份有限公司 总经理工作细则 第二章 总经理 第四条 公司设总经理一名，由董事会聘任或解聘。公司董事可受聘兼任公 司总经理。 仙乐健康科技股份有限公司 总经理工作细则 （草案） （H 股发行上市后适用） 第一章 总则 第一条 为明确仙乐健康科技股份有限公司（以下简称"公司"）总经理职责 权限，规范经营管理者的行为，完善公司法人治理结构，依据《中华人民共和 国公司法》（以下简称"《公司法》"）《香港联合交易所有限公司证券上市规 则 》（ 以下简称"《香港上市规则》"）等法律法规规范性文件规定和《仙乐健 康科技股份有限公司章程》（以下简称"公司章程"），特制定本工作细则。 第二条 总经理及其他高级管理人员应当严格按照法律法规规范性文件和公 司章程，忠实、勤勉地履行职责。 第三条 总经理及其他高级管理人员履行职责应当符合公司和全体股东的最 大利益，以合理的谨慎、注意和应有的能力在其职权和授权范围内处理公司事 务，不得利用职务便利，从事损害公司和股东利益的行为。 第五条 公司总经理专职在公司工作，不得在公司控股股东、实际控制人及 其控制的其他企业中担任除董事、监事以外的职务。 第六条 总经理任职应当具备下 ...